ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SLN Silence Therapeutics Plc

535.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 535.00 521.00 524.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Silence Therapeutics PLC Update on litigation matters (8685W)

20/11/2017 7:00am

UK Regulatory


Silence Therapeutics (LSE:SLN)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Silence Therapeutics Charts.

TIDMSLN

RNS Number : 8685W

Silence Therapeutics PLC

20 November 2017

Update on litigation matters

20 November 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces an update on litigation matters. Previously, Alnylam UK Limited and The Medicines Company UK Limited sued to revoke the relevant Silence European patent EP 2 258 847B in the UK, and also included claims for declarations of non-infringement of EP 2 258 847B by certain Alnylam products.

Silence has now served its Defence in the actions initiated by Alnylam and The Medicines Company and has counterclaimed for threatened infringement of the Silence European patent EP 2 258 847B by these companies. If successful, products including patisiran, fitusiran, givosiran and inclisiran will be found to infringe EP 2 258 847B.

Further, Silence notes that Alnylam and The Medicines Company are yet to serve their respective Defences in relation to the earlier served action brought by Silence for a declaration as to its entitlement to claim SPC protection on products containing the above-named active substances.

Silence continues to regard these actions from all parties as simply "normal course of business" at the commencement of litigation, and continues to believe that certain Alnylam products require a licence under the Silence patent estate.

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

"We continue to believe that our fundamental chemical modification technology is core foundational innovation for today's RNAi sector, and that therefore those companies using such modification technology within the scope of our Intellectual Property (IP) will require a licence."

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser        Tel: +44 (0)20 
  and Broker)                             7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                        Tel: +44 (0) 
  FTI Consulting                          20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGGGGGUPMGCM

(END) Dow Jones Newswires

November 20, 2017 02:00 ET (07:00 GMT)

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Your Recent History

Delayed Upgrade Clock